Drug Profile
BI 765179
Alternative Names: BI-765179Latest Information Update: 17 Aug 2023
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action CD137 antigen antagonists; Fibroblast activation protein antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 04 Aug 2023 Boehringer Ingelheim reinitiates a phase I trial in Solid tumours (Monotherapy, Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, Spain, Netherlands, Japan, Italy and USA (IV) for safety analysis (NCT04958239) (EudraCT2021-000234-34)
- 29 Jun 2023 Boehringer Ingelheim suspends a phase I trial in Solid tumours (Monotherapy, Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, Spain, Netherlands, Japan, Italy and USA (IV) for safety analysis (NCT04958239)
- 24 Sep 2021 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in Belgium, Spain (IV) (NCT04958239)